Recombinant alpha interferon in metastatic renal cell carcinoma. A cooperative phase II study.
A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 x 10(6) IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in 1 patient (1.63%), and toxicities greater than WHO grade 2 were present in 10 cases (16%). The overall response rate after six months of treatment was 13.1% (partial response 4, minor response 4). Two complete responses were obtained at nine and fifteen months (3.3%). Long-lasting stabilization of disease was 13.1 percent.
Bono
A V
AV
Regional Hospital, Varese, Italy.
Reali
L
L
Benvenuti
C
C
Rigatti
P
P
Gibba
A
A
Cosciani-Cunico
S
S
Brausi
M
M
Vicini
D
D
Pavone-Macaluso
M
M
Anselmo
G
G
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction
D007370:Interferon Type I; D011994:Recombinant Proteins